Amundi Boosts Stock Position in Sanofi (NASDAQ:SNY)

Amundi lifted its holdings in Sanofi (NASDAQ:SNY) by 11.1% in the fourth quarter, HoldingsChannel reports. The firm owned 630,063 shares of the company’s stock after purchasing an additional 63,195 shares during the quarter. Amundi’s holdings in Sanofi were worth $31,017,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC bought a new stake in Sanofi in the fourth quarter worth $25,000. McClarren Financial Advisors Inc. lifted its position in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Sunbelt Securities Inc. lifted its position in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the last quarter. Sierra Ocean LLC bought a new stake in Sanofi in the fourth quarter worth $44,000. Finally, Versant Capital Management Inc bought a new stake in Sanofi in the fourth quarter worth $54,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Down 1.8 %

NASDAQ:SNY opened at $57.69 on Thursday. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a market cap of $146.41 billion, a price-to-earnings ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The stock has a fifty day simple moving average of $53.27 and a 200-day simple moving average of $52.81. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on SNY shares. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.